NDAORALTABLET, CHEWABLE
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
DROSPIRENONE (drospirenone) by Xeltis is ovulation. Approved for contraception. First approved in 2022.
Drug data last refreshed 20h ago
Mechanism of Action
ovulation.
Indications (1)
Clinical Trials (20)
A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
Started Jul 2026
50 enrolled
HypertensionPreeclampsia
Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®
Started Mar 2024
32 enrolled
Healthy Subjects
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
Started Feb 2024
32 enrolled
Healthy Subjects
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
Started Aug 2023
37 enrolled
Healthy Volunteers
Drospirenone-only Pill as Emergency Contraception
Started Feb 2023
35 enrolled
Contraception
Worked on DROSPIRENONE at Xeltis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.